Daniel Herchenhorn

Dr. Daniel Herchenhorn


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RGRohan Garje
Rohan Garje
IRIrbaz Bin Riaz
Irbaz Bin Riaz
SNSyed Arsalan Ahmed Naqvi
Syed Arsalan Ahmed Naqvi
RRR. Bryan Rumble
R. Bryan Rumble
MTMary-Ellen Taplin
Mary-Ellen Taplin
RPRahul A. Parikh
Rahul A. Parikh
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE: To provide evidence-based recommendations for patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: An Expert Panel including patient representation completed a systematic review of the evidence and made recommendations. RESULTS: Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemotherapeutic agents (docetaxel, cabazitaxel), radiopharmaceuticals (radium 223, 177 Lu-prostate-specific membrane antigen [PSMA]-617), and sipuleucel-T have demonstrated an overall survival (OS) benefit for patients with mCRPC. For patients with BRCA1 / 2 alterations who did not receive prior ARPI, the combination of PARPi and ARPI (talazoparib + enzalutamide, olaparib and/or niraparib + abiraterone) has shown clinical benefit. For patients with BRCA1 / 2 alterations who received prior ARPI or ARPI followed by docetaxel, olaparib showed OS benefit. In select patients with microsatellite instability-high/mismatch repair-deficient, pembrolizumab showed clinical efficacy. RECOMMENDATIONS: Prior systemic therapy for castration-sensitive prostate cancer will determine subsequent therapy used for mCRPC. Continue androgen-deprivation therapy for patients with mCRPC indefinitely. Early adoption of somatic genetic testing and palliative care is recommended. Patients with mCRPC and bony metastases should receive a bone-protective agent. The panel recommends the combination of ARPI with PARPi in patients with BRCA1 / 2 alterations who did not receive prior ARPI. For patients who received prior ARPI, the panel recommends docetaxel chemotherapy. The panel recommends 177 Lu-PSMA-617 or cabazitaxel chemotherapy for patients who receive prior ARPI and docetaxel chemotherapy. For patients with BRCA1 / 2 alterations who received prior ARPI, the panel recommends PARPi monotherapy. Radium 223 is recommended for patients with symptomatic bone–only disease. Evidence for optimal sequencing for mCRPC regimens is lacking. Additional information is available at www.asco.org/genitourinary-cancer-guidelines .

1 November 2010 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
DHDaniel Herchenhorn
Daniel Herchenhorn
FDFernando L. Dias
Fernando L. Dias
CVCélia M.P. Viegas
Célia M.P. Viegas
MFMiriam H. Federico
Miriam H. Federico
CACarlos Manoel M. Araújo
Carlos Manoel M. Araújo
RMRenato G. Martins
Renato G. Martins

1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
FMFernando Cotait Maluf
Fernando Cotait Maluf
FPFelipe Moraes Toledo Pereira
Felipe Moraes Toledo Pereira
ASAdriano Gonçalves Silva
Adriano Gonçalves Silva
ADAldo Lourenço Abbade Dettino
Aldo Lourenço Abbade Dettino
ACAna Paula Garcia Cardoso
Ana Paula Garcia Cardoso
SGSilke Gillessen
Silke Gillessen
PURPOSE: To present a summary of the recommendations for the treatment and follow-up for metastatic castration-resistant prostate cancer (mCRPC) as acquired through a questionnaire administered to 99 physicians working in the field of prostate cancer in developing countries who attended the Prostate Cancer Consensus Conference for Developing Countries. METHODS: A total of 106 questions out of more than 300 questions addressed the use of imaging in staging mCRPC, treatment recommendations across availability and response to prior drug treatments, appropriate drug treatments, and follow-up, and those same scenarios when limited resources needed to be considered. Responses were compiled and the percentages were presented by clinicians to support each response. Most questions had five to seven relevant options for response including abstain and/or unqualified to answer, or in the case of yes or no questions, the option to abstain was offered. RESULTS: Most of the recommendations from this panel were in line with prior consensus, including the preference of a new antiandrogen for first-line therapy of mCRPC. Important aspects highlighted in the scenario of limited resources included the option of docetaxel as treatment preference as first-line treatment in several scenarios, docetaxel retreatment, consideration for reduced doses of abiraterone, and alternative schedules of an osteoclast-targeted therapy. CONCLUSION: There was wide-ranging consensus in the treatment for men with mCRPC in both optimal and limited resource settings.

1 November 2008 in ORL
Verified
Journal Article
Closed access
DHDaniel Herchenhorn
Daniel Herchenhorn
FDFernando L. Dias
Fernando L. Dias
CFCarlos G. Ferreira
Carlos G. Ferreira
CACarlos M. Araújo
Carlos M. Araújo
RLRoberto A. Lima
Roberto A. Lima
JKJacob Kligerman
Jacob Kligerman
Hypothesis: The combination of chemotherapy and radiotherapy is a standard nonsurgical treatment for locally advanced laryngeal cancer. Nevertheless, there are no validated markers to predict the outcome of nonsurgical therapies. The impact of previous tracheotomy is not clear in patients submitted to concomitant chemoradiotherapy. Study Design: A non-randomized prospective study. Prognostic factors such as stage, age, performance status, number of chemotherapy cycles, radiotherapy dose, stage VIb disease, and previous tracheotomy were analyzed using the Cox’s proportional hazard model. The Kaplan-Meier and log rank tests were used to evaluate the progression-free and overall survival. Patients and Methods: Patients with stage III/IV laryngeal carcinoma were prospectively selected. Treatment consisted of cisplatin 100 mg/m2 every 3 weeks for 3 cycles, radiotherapy to a total dose of 70.2 Gy and salvage surgery. Results: Forty-nine patients were analyzed; tracheotomy was performed in 12 patients (24.5%) before therapy. Patients who had previous tracheotomy had a lower rate of complete response (41.7 vs. 75%, p = 0.034, HR 0.55, CI 95% 0.27–1.11), shorter progression free-survival (HR 2.83, CI 95% 1.60–4.88, p < 0.001), and median overall survival (12 vs. 56 months, HR 2.37, CI 95% 1.43–3.93, p < 0.001), in comparison to those without a tracheotomy. Moreover a significant difference was observed in 3-year survival rates (6 vs. 61%, p = 0.001), in favor of the group without tracheotomy. Interestingly, the impact of previous tracheotomy was not altered when adjusted by other prognostic factors (HR 8.7, CI 95% 3.1–24.0, p < 0.001). Conclusions: Previous tracheotomy is a negative prognostic factor for patients submitted to chemotherapy combined with radiotherapy and should be considered as a negative clinical prognostic factor in the selection of patients for more aggressive treatment strategies.

23 May 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GWGustavo Werutsky
Gustavo Werutsky
FMFernando Cotait Maluf
Fernando Cotait Maluf
ECEduardo Henrique Cronemberger
Eduardo Henrique Cronemberger
VSVinicius Carrera Souza
Vinicius Carrera Souza
SMSuelen Patricia dos Santos Martins
Suelen Patricia dos Santos Martins
AFAndré Fay
André Fay
Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients’ quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk. We hypothesized that abiraterone acetate with prednisone (AAP) and apalutamide, alone or in combination, can be an effective hormonal therapy also possibly decreasing castration-associated side effects. Phase II, open-label, randomized, efficacy trial of abiraterone acetate plus prednisone (AAP) and Androgen Deprivation Therapy (ADT) versus apalutamide versus the combination of AAP (without ADT) and apalutamide. Key eligibility criteria are confirmed prostate adenocarcinoma; biochemical relapse after definitive treatment (PSA ≥ 4 ng/ml and doubling time less than 10 months, or PSA ≥ 20 ng/ml); newly diagnosed locally advanced or metastatic prostate cancer; asymptomatic to moderately symptomatic regarding bone symptoms. Patients with other histology besides adenocarcinoma or previous use of hormonal therapy or chemotherapy were excluded. There is an urgent need to study and validate regimens such as new hormonal agents that may add benefit to castration with an acceptable safety profile. We aim to evaluate if apalutamide in monotherapy or in combination with AAP is an effective and safety hormonal treatment that can spare patients of androgen deprivation therapy. This trial was registered in ClinicalTrials.gov on October 16, 2017, under Identifier: NCT02867020.

7 March 2022 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
FHFabiana Hottz
Fabiana Hottz
DHDaniel Herchenhorn
Daniel Herchenhorn
JLJuliana Lenzi
Juliana Lenzi
JAJuliana Andrade
Juliana Andrade
VFVinicius Freire
Vinicius Freire
PPPedro Pinho
Pedro Pinho
In-field dermatitis is a severe and common adverse effect of radiation therapy, that can cause significant pain and treatment interruptions in patients with squamous cell anal carcinoma (SCAC) being treated with radical chemoradiation protocols. There are no established therapies for the treatment of radiation induced dermatitis. Photobiomodulation (PBM) is an effective and low-cost treatment for radiation induced mucositis, but have recently been explored to treat in-field dermatitis. We present a case report of the successful use of PBM for the treatment of dermatitis in the anal area in a patient with SCAC treated with concomitant chemoradiation with curative intent and follow with a literature review of the recent advances and possibilities of the use of PBM as a promising strategy. PBM therapy proved to be efficient in the radiodermatitis treatment, both in relieving the symptoms and controlling dermatitis, in addition to improving the patient's quality of life.